United States has already PAID $9.836 Billion for 800 Million Doses of Unproven COVID-19 Vaccines

America Orders-

  1. 300 Million Doses of Oxfords and AstraZeneca’s AZT1222. COST-$1.2 Billion for 300 Million Doses.
  2. 100 Million Doses of PFIZER AND BIONTECH’s BNT162. With an agreement to possibly buy an additional 500 Million Doses. COST-$1.95 Billion for 1st 100 Million.
  3. 100 Million Doses of Moderna’s mRNA-1273. With an agreement to buy an additional 400 Million Doses. COST-$1.53 Billion for 1st 100 Million Doses.
  4. 100 Million Doses of Johnson & Johnson’s Ad26.COV2-S. With an agreement to purchase an additional 200 Million Doses. COST-$1.456 Billion for 1st 100 Million Doses.
  5. 100 Million Doses-The U.S. announced Friday it will pay drugmaker Sanofi and GlaxoSmithKline up to $2.1 billion to develop and deliver 100 million doses of their potential vaccine.  COST-$2.1 Billion.
  6. U.S. Government giving NOVAVAX $1.6 Billion for 100 Million Doses of an undetermined COVID Vaccine?
  7. Grand Total-$9.836 Billion for 800 Million Doses. ***With Options to buy another 1.1 Billion Doses. Some Vaccines require One Shot, then 2nd Shot in 28 Days. Some Vaccines have not begun Phase I Testing. Some are entering Phase III Testing.
  8. America could see Vaccines available as EARLY as October of this year. With an EXTREME outbreak of Cases and Deaths, the FDA at that point might make a Vaccine Candidate available on an EMERGENCY USE ONLY Basis. I still like Oxfords and now with AstraZeneca’s manufacturing capabilities, this could be a good Choice. It addresses Two things in its Vaccine.
  • May 12: DoD and HHS announced a $138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end 2020, as well as the development of manufacturing capacity for the ultimate production goal of over 500 million prefilled syringes in 2021.
  • June 9: HHS and DoD announced a joint effort to increase domestic manufacturing capacity for vials that may be needed for vaccines and treatments:
    • $204 million to Corning to expand the domestic manufacturing capacity to produce an additional 164 million Valor Glass vials each year if needed.
    • $143 million to SiO2 Materials Science to ramp up capacity to produce the company’s glass-coated plastic container, which can be used for drugs and vaccines.

How is this being funded?

Congress has directed almost $10 billion to this effort through supplemental funding, including the CARES Act. Congress has also appropriated other flexible funding. The almost $10 billion specifically directed includes more than $6.5 billion designated for countermeasure development through BARDA and $3 billion for NIH research.